Loading
NI
Neurotrope, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SCHECHTER JONATHAN, was filed 02 Nov 2020.
Neurotrope, Inc.: what insiders have been doing
Neurotrope, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Neurotrope, Inc. in twelve months, the latest record being from 3 December 2020.
Since 2016, the database holds 9 purchases and 2 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
19
Thresholds
n/a
Buy Volume
€175,739
9 ops. · all time
Sell Volume
€2,136
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2019FY ended December 2019 · cache
Income statement
Net income-13.5M
Last declaration on 3 December 2020
Declarations19 total
29,688 sharesCommon StockSEC:0001104659-20-132155:0
1,565 sharesCommon StockSEC:0001104659-20-132152:0
50,000 sharesCommon StockSEC:0001104659-20-132148:0
3,953 sharesCommon StockSEC:0001104659-20-132150:0
100,000 sharesCommon StockSEC:0001104659-20-132149:0
25,000 shares@ US$0.977731.0% of flowCommon StockSEC:0001104659-20-120279:0
Canonical exit: 28 Jan 2021 (T+90)
25,000 shares@ US$1.1034.5% of flowCommon StockSEC:0001104659-20-118010:0
Canonical exit: 20 Jan 2021 (T+90)
2,012 shares@ US$1.102.8% of flowCommon StockSEC:0001104659-20-117012:0
Canonical exit: 18 Jan 2021 (T+90)
22,988 shares@ US$1.1031.6% of flowCommon StockSEC:0001104659-20-117012:1
Canonical exit: 19 Jan 2021 (T+90)
50,000 shares@ US$1.088950.5% of flowCommon StockSEC:0001104659-20-116286:0
Canonical exit: 14 Jan 2021 (T+90)
50,000 shares@ US$1.066349.5% of flowCommon StockSEC:0001104659-20-115850:0
Canonical exit: 13 Jan 2021 (T+90)
157 shares@ US$8.5350.7% of flowCommon StockSEC:0001144204-18-015273:0
157 shares@ US$8.3149.3% of flowCommon StockSEC:0001144204-18-015273:1
41,667 shares@ US$0.01100.0% of flowCommon StockSEC:0001144204-16-140449:0
50,000 shares@ US$0.2795100.0% of flowCommon StockSEC:0001144204-16-137638:0
Canonical exit: 2 Mar 2017 (T+90)
5,000 shares@ US$0.2942.9% of flowCommon StockSEC:0001144204-16-136602:0
Canonical exit: 21 Feb 2017 (T+90)
17,242 shares0Common StockSEC:0001144204-16-135757:0
43,104 shares0Common StockSEC:0001144204-16-135758:0
5,000 shares@ US$0.4157.1% of flowCommon StockSEC:0001144204-16-121588:0
Canonical exit: 24 Nov 2016 (T+90)
19 of 19 declarations
About Neurotrope, Inc.
Neurotrope, Inc. is a company focused on developing treatments for neurodegenerative diseases. It is listed on the XNAS market.
